SCHEMBL1443330

SCHEMBL1443330

NCc1nc(-c2ccccn2)ncc1Cc1ccccc1F

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 7/20 0.57
NPC1 O15118 5/20 0.57
HTT P42858 4/20 0.57
RAB9A P51151 4/20 0.57
ALDH1A1 P00352 4/20 0.57
SMN1; SMN2 Q16637 5/20 0.42
TDP1 Q9NUW8 2/20 0.42
PPP1CA P62136 2/20 0.42
TRPM8 Q7Z2W7 2/20 0.41
ADORA2A P29274 1/20 0.40
ADORA1 P30542 1/20 0.40
KDM4E B2RXH2 3/20 0.39
ALOX15 P16050 1/20 0.38
FFAR1 O14842 1/20 0.36
GRM5 P41594 1/20 0.36
TP53 P04637 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1442705 0.82 L3MBTL1 (0.56) L3MBTL1NPC1HTTRAB9AALDH1A1
SCHEMBL1443023 0.82 L3MBTL1 (0.56) L3MBTL1NPC1HTTRAB9AALDH1A1
SCHEMBL1442850 0.81 NPC1 (0.48) L3MBTL1NPC1HTTRAB9AALDH1A1
SCHEMBL1443331 0.80 L3MBTL1 (0.54) L3MBTL1NPC1HTTRAB9AALDH1A1
SCHEMBL1442644 0.77 HTT (0.51) L3MBTL1NPC1HTTRAB9AALDH1A1
SCHEMBL27855828 0.76 NPC1 (0.59) L3MBTL1NPC1HTTRAB9AALDH1A1
SCHEMBL1442954 0.76 TRPM8 (0.70) L3MBTL1NPC1HTTRAB9AALDH1A1
SCHEMBL1442846 0.76 NPC1 (0.50) L3MBTL1NPC1HTTRAB9AALDH1A1
SCHEMBL11900690 0.75 L3MBTL1 (0.51) L3MBTL1NPC1HTTRAB9AALDH1A1
SCHEMBL23837651 0.73 GUCY1B2 (0.49) L3MBTL1NPC1HTTRAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2473486-B2 PYRIMIDINES AS HEPCIDINE ANTAGONISTS VIFOR INT AG (CH) 2021-09-22 EP disclosed
EP-2473486-B1 PYRIMIDINES AS HEPCIDINE ANTAGONISTS VIFOR INT AG (CH) 2015-10-28 EP disclosed
US-20120202806-A1 Novel Pyrimidine- And Triazine-Hepcidine Antagonists VIFOR (INTERNATIONAL) AG (CH) 2012-08-09 US disclosed
EP-2473486-A1 NOVEL PYRIMIDINE AND TRIAZINE HEPCIDINE ANTAGONISTS VIFOR (INTERNATIONAL) AG (CH) 2012-07-11 EP disclosed
WO-2011026835-A1 NOVEL PYRIMIDINE AND TRIAZINE HEPCIDINE ANTAGONISTS VIFOR (INTERNATIONAL) AG (CH) 2011-03-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202806-A1 Novel Pyrimidine- And Triazine-Hepcidine Antagonists HAMP, DHPS, SLC40A1 L3MBTL1 3829/4885NPC1 2222/4885HTT 2057/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.